In 2019, Indonesia and the other countries in the WHO South-East Asia Region adopted the goal of measles and rubella elimination by 2023. This report describes Indonesia's progress during 2013-2022. Coverage with a first dose of measles-containing vaccine (MCV) decreased from 87% to 84%, and coverage with a second MCV dose decreased from 76% to 67%. After rubella vaccine was introduced in 2017, coverage with the first dose of rubella-containing vaccine increased by 5 times, from 15% in 2017 to 84% in 2022. During 2013-2021, the annual reported measles incidence decreased by 95%, from 33.2 to 1.4 cases per million population, and the reported rubella incidence decreased by 89%, from 9.3 to 1.0 cases per million population. A large upsurge in measles and rubella cases occurred in 2022, however, with a reported measles incidence of 29 cases per million population and a reported rubella incidence of 3 per million, due primarily to the disruption in immunization services by the coronavirus disease 2019 (COVID-19) pandemic. In 2022, >26 million children (an estimated 73% of the target population) received a combined measles- and rubella-containing vaccine (measles and rubella CV) during supplementary immunization activities in 32 provinces. Although progress has been made towards measles and rubella elimination in Indonesia, continued and urgent efforts are necessary to restore routine immunization services and to close gaps in order to accelerate progress towards elimination.